Roche Holdings Ltd.
) recently announced that its new viral load test is now available
in the US. The fully automated COBAS AmpliPrep / COBAS TaqMan CMV
test aims to assess a patient's viral load of cytomegalovirus
In July 2012, Roche had received premarket approval (PMA) from
the US Food and Drug Administration (FDA) for this test. This is
the first FDA-approved laboratory test for use in quantifying CMV
DNA in human plasma specimens. The information from the test is
used by physicians to manage patients who have been diagnosed with
As per company sources, around 50-80% of the total population in
the US are infected with CMV, the most common viral infection among
solid organ transplant recipients.
Notably, Roche's product portfolio includes Valcyte for the
treatment of CMV retinitis in patients with acquired
immunodeficiency syndrome (AIDS). Valcyte sales amounted to CHF 307
million in the first half of 2012.
Recently, Roche provided an update on its research and
development (R&D) programs and its strategy on innovation for
unmet medical needs. The company expects results from 19 late-stage
clinical trials in the next 18 months.
Of these, 12 studies are investigating new molecular entities
(NMEs). Moreover, Roche expects three additional NMEs to reach the
Lifecycle Investment Point (LIP) and move to late-stage development
by year end. Roche allotted half of its R&D budget to its
Roche moreover implemented rigorous portfolio prioritisation,
new development designs, and cost-saving initiatives to keep its
R&D budget stable despite its significant pipeline
Roche, headquartered in Basel, Switzerland, carries a Zacks #4
Rank (Sell rating) in the short run.
(RHHBY): ETF Research Reports
To read this article on Zacks.com click here.